Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-SARS-CoV-2 monoclonal antibodies AZD5156

A combination of two neutralizing human monoclonal antibodies, cilgavimab, a neutralizing human monoclonal antibody directed against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike (S) protein, and AZD3152, a long-acting neutralizing human monoclonal antibody directed against SARS-CoV-2, derived from B cells of convalescent patients with SARS-CoV-2 infection, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration of anti-SARS-CoV-2 monoclonal antibodies AZD5156, cilgavimab specifically targets and binds to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. Anti-SARS-CoV-2 monoclonal antibody AZD3152 also neutralizes SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:AZD1061 plus AZD3152
AZD1061/AZD3152
cilgavimab Plus AZD3152
cilgavimab/AZD3152
Code name:AZD 5156
AZD-5156
AZD5156
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search